Skip To Main Content
Určeno pro odbornou veřejnost
Campus
Campus
View Full Results

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
EADV24 Highlights

EADV24 Highlights

Číst více
EADV24 Highlights

EADV24 Highlights

Číst více
Choroby Gauchera i ASMD. Co zrobić by o nich pamiętać w praktyce lekarskiej?

Choroby Gauchera i ASMD. Co zrobić by o nich pamiętać w praktyce lekarskiej?

Objawy kliniczne: splenomegalia, małopłytkowość, niedokrwistość...

Objawy niespecyficzne, różnorodne...

Kiedy podejrzewać chorobę Gauchera w praktyce lekarza hematologa, pediatry?

Zapraszamy do obejrzenia dyskusji Ekspertów - Konferencja PTOiHD 2024.

Číst více
חיסון למניעת RSV

חיסון למניעת RSV

Číst více
Tọa Đàm Trực Tuyến Cập Nhật Các Tiến Bộ Trong Phẫu Thuật Thẩm Mỹ & Chấn Thương Chỉnh Hình - Vai Trò Của Alphachymotrypsine Trên Lâm Sàng

Tọa Đàm Trực Tuyến Cập Nhật Các Tiến Bộ Trong Phẫu Thuật Thẩm Mỹ & Chấn Thương Chỉnh Hình - Vai Trò Của Alphachymotrypsine Trên Lâm Sàng

Číst více
Program lekowy B.164. LECZENIE PACJENTÓW Z IMMUNOLOGICZNĄ ZAKRZEPOWĄ PLAMICĄ MAŁOPŁYTKOWĄ (ICD-10: M31.1)

Program lekowy B.164. LECZENIE PACJENTÓW Z IMMUNOLOGICZNĄ ZAKRZEPOWĄ PLAMICĄ MAŁOPŁYTKOWĄ (ICD-10: M31.1).

Serdecznie zapraszamy do zapoznania się z materiałem.

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více
One minute to ignite new thinking in COPD

One minute to ignite new thinking in COPD

Understanding type 2 inflammation* may help shed light on why some patients continue to exacerbate. Watch this video to learn how.1

Číst více